Skip to main content

Transdermal Skin Patches Market will generate new growth opportunities 2023-2028

 


Transdermal patches are a method of drug delivery in which an adhesive patch provides a pre-prescribed dose of medication that is absorbed through the skin and into the bloodstream. The term ‘transdermal’ describes a delivery method used for administering pharmaceuticals. These patches are designed for short-term or long-term administration and can either be electronic or mechanical. Transdermal patches adhere to the skin as a way to deliver drugs. They provide a specific, predetermined dose of medicine which is absorbed through the skin and into the blood. Although comparable to oral-dosage forms in efficacy, skin patches have several advantages over oral forms. They provide a non-invasive and painless method of drug delivery.

Market Statistics:

The global transdermal skin patches market was valued at US$ 7,695.0 Mn in 2021 and is forecast to reach a value of US$ 10,839.7 Mn by 2028 at a CAGR of 5.0% between 2022 and 2028.

Market Drivers:

1.      Growing adoption of transdermal skin patches is expected to boost the growth of the global transdermal skin patches market during the forecast period. For instance, in December 2020, Agile Therapeutics, Inc. announced the U.S. commercial launch of Twirla (levonorgestrel and ethinyl estradiol) transdermal system, a new non-daily, non-invasive contraceptive patch. It is now available in the U.S. by prescription for women of reproductive potential with a BMI 30 kg/m2. It is designed to be worn on the abdomen, buttock, or upper torso (excluding breasts).

2.      Growing funding and investments for drug development is expected to propel the growth of the global transdermal skin patches market over the forecast period. For instance, in May 2019, Mercia invested £2.0 million in transdermal drug delivery specialist Medherant Limited. This latest investment will enable Medherant to finalize the selection of three TEPI Patch products to take into clinical development. The development of patch products that will bring significant benefits to patients across the globe.

 

Comments

Popular posts from this blog

Life Sciences BPO Market is Expected to Grow Drastically, Assured By Experts From 2023 To 2028

  The growing cost of drug development is augmenting the growth of the global life sciences BPO market. For instance, according to a study by the Tufts Center for the Study of Drug Development published in the Journal of Health Economics in May 2019, the cost of drug development was US$ 2.6 billion, which included average out-of-pocket costs of US$ 1.4 billion and time costs of US$ 1.2 billion. Also, patent expiration is another key factor propelling the growth of the life sciences BPO market. For instance, the patent for YAZ (drospirenone/ethinylestradiol), which provides an oral contraceptive regimen, is set to expire in 2021. Furthermore, the rising prevalence of chronic disease around the globe is further anticipated to accelerate the growth of the market. North America is projected to lead the global life sciences BPO market due to increasing R&D in cell therapies by key players in the region. For instance, in February 2020, Caribou Biosciences, Inc., a CRISPR genome editin

Increasing various research activities is propelling growth of the pediatric vaccines market

  Pediatric Vaccine Market: Global Trends Over the course of the forecast period, rising public awareness of vaccinations and immunisation is anticipated to fuel market expansion for paediatric vaccines worldwide. For instance, the United States recognises January as Cervical Health Awareness Month, promoting the value of routine immunisation and screening in the fight against cancer. Global Pediatric Vaccine Market: Drivers Increasing awareness regarding vaccines and immunization among the populace is expected to boost growth of the global pediatric vaccine market over the forecast period. For instance, in the U.S., the month of January is celebrated as Cervical Health Awareness Month, wherein the importance of regular vaccination and screening in the prevention of cancer is forwarded.

Epidermolysis Bullosa Therapeutics Market Is Booming Worldwide 2023-2028

  Epidermolysis bullosa is a group of rare inherited skin disorders that causes the skin to become very fragile. Any trauma or friction to the skin can cause painful blisters. The symptoms of epidermolysis bullosa include skin that blisters easily, blisters on hands and soles of the feet, thickened skin that may be scarred or change color over time, and thickening of the skin and nails. There are three types of epidermolysis bullosa which includes: ·          Epidermolysis bullosa simplex (EBS) – the most common type, which can range from mild, with a low risk of serious complications to severe ·          Dystrophic epidermolysis bullosa (DEB) – which can range from mild to severe ·          Junctional epidermolysis bullosa (JEB) – a rare form of epidermolysis bullosa that ranges from moderate to severe The type reflects where on the body the blistering takes place and which layer of skin is affected. Global epidermolysis bullosa market is estimated to be valued at  US$ 3,